Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
18 Aprile 2024 - 11:29PM
Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug
development company for treatment of bacterial skin infections,
today announced that it has filed voluntary petitions for relief
under subchapter V of Chapter 11 of the U.S. Bankruptcy Code
(“Chapter 11”) in the United States Bankruptcy Court for the
Southern District of California to confirm a plan of liquidation
that will distribute all value to stakeholders, including
shareholders.
Histogen intends to promptly propose and confirm a plan of
liquidation and make distributions to the benefit of its estate.
The Company announced on Sept. 18, 2023, that it had discontinued
further development and would seek approve for a Plan of
Dissolution.
Histogen is represented by DLA Piper, LLP as its legal counsel
and Armanino LLP as its financial advisor.
ABOUT HISTOGENHistogen Inc. was a
clinical-stage therapeutics company focused on developing potential
clinical and preclinical drugs for a variety of antiapoptotic and
anti-inflammatory effects.
MEDIA CONTACT
Martin Stein
AMF Media Group
martin@amfmediagroup.com
Grafico Azioni Histogen (NASDAQ:HSTO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Histogen (NASDAQ:HSTO)
Storico
Da Mag 2023 a Mag 2024